Skip to main content

Table 1 Baseline demographic and clinicohistologic characteristics of the patients described in this study

From: Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer

Clinicohistologic feature n (%)
Age, median [range] 60 [20–79]  
Sex Female 16 (22.5)
  Male 54 (76.1)
  Unknown 1 (1.4)
Stage III 22 (31)
IV 48 (67.6)
Unknown 1 (1.4)
Histology LUAD 56 (78.9)
LUSC 15 (21.1)
Smoking Yes 33 (46.5)
No 38 (53.5)
Location of lung tumor Central 39 (54.9)
Peripheral 28 (39.4)
Unknown 4 (5.6)
Sputum type Induced 13 (18.3)
Non-induced 58 (81.7)
T stage T1 9 (12.7)
  T2 19 (26.8)
  T3 15 (21.1)
  T4 28 (39.4)
N stage N0 1 (1.4)
  N1 7 (9.9)
  N2 22 (31)
  N3 40 (56.3)
  Unknown 1 (1.4)
M stage M0 19 (26.8)
  M1 48 (67.6)
  Unknown 4 (5.6)
Nodal metastasis Yes 68 (95.8)
No 2 (2.8)
Unknown 1 (1.4)
Brain metastasis Yes 12 (16.9)
No 58 (81.7)
Unknown 1 (1.4)
Pleural metastasis Yes 27 (38.0)
No 43 (60.6)
Unknown 1 (1.4)
Bone metastasis Yes 12 (16.9)
No 58 (81.7)
Unknown 1 (1.4)
Tracheal violation Yes 23 (32.4)
No 44 (62.0)
Unknown 4 (5.6)
Blood vessel invasion Yes 12 (16.9)
No 56 (78.9)
Unknown 3 (4.2)
Pleurisy Yes 19 (26.8)
No 48 (67.6)
Unknown 4 (5.6)
  1. LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma